Acurx Pharmaceuticals, Inc. (ACXP): Price and Financial Metrics

Acurx Pharmaceuticals, Inc. (ACXP): $2.90

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add ACXP to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#NR of NR

in industry

ACXP Price/Volume Stats

Current price $2.90 52-week high $4.85
Prev. close $2.90 52-week low $2.33
Day low $2.81 Volume 5,700
Day high $2.91 Avg. volume 30,779
50-day MA $3.11 Dividend yield N/A
200-day MA $3.40 Market Cap 33.85M

ACXP Stock Price Chart Interactive Chart >


Acurx Pharmaceuticals, Inc. (ACXP) Company Bio


Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.


ACXP Latest News Stream


Event/Time News Detail
Loading, please wait...

ACXP Latest Social Stream


Loading social stream, please wait...

View Full ACXP Social Stream

Latest ACXP News From Around the Web

Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.

Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,333,333 shares of its common stock (or pre-funded warrants in lieu thereof) at a combined effective purchase price of $3.00 per share (or pre-funded warrant) in a registered direc

Yahoo | May 16, 2023

Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2023.

Yahoo | May 12, 2023

Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2023 financial results on Friday, May 12, 2023, at 8:00 am ET before the U.S. financial markets open.

Yahoo | May 5, 2023

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | April 22, 2023

New to The Street Announces its Corporate Interviews, Episodes 459 and 460 With the TV Shows Airings to Start on Saturday, April 22, 2023, at 3:30 PM ET

New to The Street Announces its Corporate Interviews, Episodes 459 and 460 Featuring the following:1).Acurx Pharmaceuticals, Inc.'(NASDAQ: ACXP) ($ACXP) 2).SMX (Security Matters), PLC.'s (NASDAQ: SMX) ($SMX).3). Linqto's 4). Hapbee Technologies, Inc. (OTCQB: HAPBF) (TSXV: HAPB) (FSE: HA1) 5).Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). 6).The Sustainable Green Team, Ltd. (OTCQX: SGTM) ($SGTM) Business TV show on 3-major Networks. NEW YORK, April 21, 2023 (GL

Yahoo | April 21, 2023

Read More 'ACXP' Stories Here

ACXP Price Returns

1-mo -5.23%
3-mo -14.45%
6-mo -21.62%
1-year 7.41%
3-year N/A
5-year N/A
YTD -27.14%
2022 -7.90%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!